Database : MEDLINE
Search on : Aniridia [Words]
References found : 2820 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 282 go to page                         

  1 / 2820 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29519880
[Au] Autor:Landsend ECS; Pedersen HR; Utheim ØA; Xiao J; Adil MY; Tashbayev B; Lagali N; Dartt DA; Baraas RC; Utheim TP
[Ad] Address:Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.
[Ti] Title:Meibomian gland dysfunction and keratopathy are associated with dry eye disease in aniridia.
[So] Source:Br J Ophthalmol;, 2018 Mar 08.
[Is] ISSN:1468-2079
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:AIMS: To investigate the aetiology and characteristics of dry eye disease (DED) in a Nordic cohort of patients with congenital aniridia. METHODS: Thirty-four Norwegian and one Danish subject with congenital aniridia and 21 healthy controls were examined. All subjects underwent an extensive dry eye examination, including evaluation of meibomian glands (MGs) by meibography, measurement of tear production and tear film osmolarity and grading of vital staining of the ocular surface. Moreover, slit-lamp biomicroscopy was undertaken, including grading of aniridia-associated keratopathy (AAK). RESULTS: Mean tear film osmolarity was significantly higher (314±11 mOsmol/L) in patients with aniridia compared with the healthy control group (303±11 mOsmol/L, p=0.002). Vital staining score was higher in the aniridia group (4.3±3.0) compared with healthy controls (2.4±1.6, p=0.02). The degree of staining correlated positively with the stage of AAK (r=0.44, p=0.008) and negatively with corneal sensitivity (r=-0.45, p=0.012). Number of expressible MGs was lower in aniridia subjects (2.9±1.6) than in controls (4.0±1.3, p=0.007). MG loss, staged from 0 to 3, was higher in the aniridia group than in the control group, both in upper eyelid (0.86±0.89 vs 0.10±0.31, p=0.001) and lower eyelid (0.94±0.73 vs 0.30±0.47, p=0.003). Computerised analyses showed thinning (p=0.004) and lower density (p<0.001) of the MGs compared with the healthy population. CONCLUSIONS: Patients with congenital aniridia demonstrate increased tear film osmolarity, ocular surface staining, loss of MGs and lower MG expressibility. We conclude that meibomian gland dysfunction and keratopathy are related to development of DED in aniridia.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  2 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29408907
[Au] Autor:Kang KB; Karas FI; Rai R; Hallak JA; Kang JJ; de la Cruz J; Cortina MS
[Ad] Address:Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, United States of America.
[Ti] Title:Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study.
[So] Source:PLoS One;13(2):e0192381, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Despite improved retention and reduced complication rates paving the way for the current expansion of applications and surge in prevalence for the Boston type I Keratoprosthesis (KPro), the most frequent indication for its implantation today remains prior graft failure. The purpose of this study is to evaluate the long-term outcomes of primary KPro and compare to secondary implantation in a matched cohort study. This study included patients who underwent KPro implantation in a single center by two surgeons between July 2008 and October 2014. All eyes with KPro implantation as the primary procedure with a minimum follow up of 12 months were matched with eyes with same preoperative diagnoses that underwent secondary KPro implantation. Main outcomes included visual acuity and device retention. A total of 56 eyes were included with 28 eyes in each group. Mean follow up was 5.0 years for both groups. Twenty-nine percent (8) of the eyes in the primary group had a diagnosis of chemical or thermal injuries, 25% (7) aniridia, 18% (5) autoimmune disease, 4% (1) infectious keratitis/neurotrophic cornea, 7% (2) gelatinous corneal dystrophy, 7% (2) ectrodactyly ectodermal dysplasia/limbal stem cell deficiency, and 11% (3) uveitis/hypotony. Sixty-one percent (17) of the eyes in the primary group and 39% (11) in the secondary group maintained a final best-corrected visual acuity of 20/200 or better at a mean follow up of 5.0 years; the probability of maintaining best-corrected vision is 0.83 and 0.49 for primary and secondary groups at 5.0 years (p = 0.02). There is no statistically significant difference between groups in device retention (p = 0.22) or postoperative complication rates (p >0.05). This study demonstrates that Boston KPro implantation may be successful as a primary procedure in patients at high risk of failure with traditional penetrating keratoplasty. The device has a good long-term retention rate and visual outcomes are promising however a larger study is needed for more definitive results.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Data-Review
[do] DOI:10.1371/journal.pone.0192381

  3 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29202485
[Au] Autor:Aguirre-Vázquez A; Sampayo-Reyes A; González-Escalante L; Hernández A; Marcos R; Castorena-Torres F; Lozano-Garza G; Taméz-Guerra R; de León MB
[Ad] Address:Universidad Autónoma de Nuevo León, UANL, Fac. De Biología, San Nicolás delos Garza, Nuevo León, Mexico.
[Ti] Title:Selenite restores Pax6 expression in neuronal cells of chronically arsenic-exposed Golden Syrian hamsters.
[So] Source:Acta Biochim Pol;64(4):635-639, 2017.
[Is] ISSN:1734-154X
[Cp] Country of publication:Poland
[La] Language:eng
[Ab] Abstract:Arsenic is a worldwide environmental pollutant that generates public health concerns. Various types of cancers and other diseases, including neurological disorders, have been associated with human consumption of arsenic in drinking water. At the molecular level, arsenic and its metabolites have the capacity to provoke genome instability, causing altered expression of genes. One such target of arsenic is the Pax6 gene that encodes a transcription factor in neuronal cells. The aim of this study was to evaluate the effect of two antioxidants, α-tocopheryl succinate (α-TOS) and sodium selenite, on Pax6 gene expression levels in the forebrain and cerebellum of Golden Syrian hamsters chronically exposed to arsenic in drinking water. Animals were divided into six groups. Using quantitative real-time reverse transcriptase (RT)-PCR analysis, we confirmed that arsenic downregulates Pax6 expression in nervous tissues by 53 ± 21% and 32 ± 7% in the forebrain and cerebellum, respectively. In the presence of arsenic, treatment with α-TOS did not modify Pax6 expression in nervous tissues; however, sodium selenite completely restored Pax6 expression in the arsenic-exposed hamster forebrain, but not the cerebellum. Although our results suggest the use of selenite to restore the expression of a neuronal gene in arsenic-exposed animals, its use and efficacy in the human population require further studies.
[Mh] MeSH terms primary: Arsenic/toxicity
Neurons/drug effects
PAX6 Transcription Factor/genetics
Sodium Selenite/pharmacology
[Mh] MeSH terms secundary: Animals
Antioxidants/pharmacology
Cerebellum/drug effects
Cerebellum/metabolism
Gene Expression Regulation/drug effects
Male
Mesocricetus
Neurons/metabolism
Neurons/pathology
Prosencephalon/drug effects
Prosencephalon/metabolism
Toxicity Tests, Chronic
alpha-Tocopherol/pharmacology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antioxidants); 0 (PAX6 Transcription Factor); H4N855PNZ1 (alpha-Tocopherol); HIW548RQ3W (Sodium Selenite); N712M78A8G (Arsenic)
[Em] Entry month:1802
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[Js] Journal subset:IM
[Da] Date of entry for processing:171205
[St] Status:MEDLINE
[do] DOI:10.18388/abp.2017_1607

  4 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29380764
[Au] Autor:Palayil I; Priya SG; Sivan NVS; Madhivanan N; Venkatachalam PS; Jagadeesan M
[Ad] Address:Arasan Eye Hospital, Erode, India.
[Ti] Title:Identification of a novel frameshift mutation in gene and the clinical management in an Asian Indian aniridia family.
[So] Source:Indian J Ophthalmol;66(2):229-232, 2018 Feb.
[Is] ISSN:1998-3689
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:PURPOSE: This study aimed to characterize an Asian Indian aniridia family for both the phenotype and genotype of the disease for a better clinical management. METHODS: The phenotype and genotype of the affected and unaffected individuals in the aniridia family were evaluated. The subjects underwent a standard ophthalmic evaluation followed by molecular screening of PAX6 gene in the peripheral blood for mutation detection. RESULTS: The three affected individuals had aniridia with several common features and an uncommon presentation of bilateral congenital ptosis. Two affected siblings, a brother and a sister, had aniridia, nystagmus, ptosis, increase in central corneal thickness, cataract, and foveal hypoplasia. The sister had features of glaucoma. The offspring of the sister had all the features except cataract and rise in intraocular pressure. Mutation screening of PAX6 gene helped in identifying a novel heterozygous pathogenic variation g. 31801757dupG (c. 216-19dupG) that resulted in a frameshift mutation that extended into exon 7. Based on the evaluation and diagnostic testing, the family was clinically managed along with genetic counselling. CONCLUSION: Molecular diagnostic testing helps in genetic counseling of the family with aniridia to understand the nature of the disease and detection of complications early for better management.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[St] Status:In-Data-Review
[do] DOI:10.4103/ijo.IJO_311_17

  5 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29460221
[Au] Autor:Wawrocka A; Krawczynski MR
[Ad] Address:Department of Medical Genetics, Poznan University of Medical Sciences, Rokietnicka 8, 60-806, Poznan, Poland. ania.wawrocka@gmail.com.
[Ti] Title:The genetics of aniridia - simple things become complicated.
[So] Source:J Appl Genet;, 2018 Feb 19.
[Is] ISSN:2190-3883
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Aniridia is a rare, panocular disorder characterized by a variable degree of hypoplasia or the absence of iris tissue associated with additional ocular abnormalities. It is inherited in an autosomal dominant manner, with high penetrance and variable expression even within the same family. In most cases the disease is caused by haploinsufficiency truncating mutations in the PAX6 gene; however, in up to 30% of aniridia patients, disease results from chromosomal rearrangements at the 11p13 region. The aim of this review is to present the clinical and genetic aspects of the disease. Furthermore, we present a molecular diagnostic strategy in the aniridia patients. Recent improvement in the genetic diagnostic approach will precisely diagnosis aniridia patients, which is essential especially for children with aniridia in order to determine the risk of developing a Wilms tumor or neurodevelopmental disorder. Finally, based on the previous studies we describe the current knowledge and latest research findings in the topic of pathogenesis of aniridia and possible future treatment.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[St] Status:Publisher
[do] DOI:10.1007/s13353-017-0426-1

  6 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29343077
[Au] Autor:Hanish AE; Han JC
[Ad] Address:1 Unit on Metabolism and Neuroendocrinology, Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
[Ti] Title:Delayed Onset of Sleep in Adolescents With PAX6 Haploinsufficiency.
[So] Source:Biol Res Nurs;20(2):237-243, 2018 Mar.
[Is] ISSN:1552-4175
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: PAX6 haploinsufficiency ( +/-) can occur due to mutations involving only PAX6 in patients with isolated aniridia or as contiguous gene deletions in patients with Wilms tumor, aniridia, genitourinary anomalies, and range of developmental and intellectual disabilities syndrome. Given the role of PAX6 in pineal development and circadian regulation, adolescents with PAX6+/- may experience sleep-wake disturbances. The purpose of this observational study was to explore sleep-related phenotypes in adolescents with PAX6+/-. METHODS: This study compared sleep phenotypes of nine subjects with PAX6+/- (aged 10-19 years) with previously published data on healthy adolescents ( n = 25, aged 10-18 years). Subjects completed the Cleveland Adolescent Sleepiness Questionnaire (CASQ), Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (v. 1.0; 8a), and PROMIS Sleep-Related Impairment (v. 1.0; 8b) Questionnaires and wore actigraphs for seven nights to record sleep patterns. RESULTS: Total CASQ, PROMIS sleep-related impairment, and PROMIS sleep disturbance scores were not statistically different between the groups ( ps > .15). Actigraph data for lights off to sleep-onset time were found to be significantly higher in subjects with PAX6+/- versus the healthy comparison group (adjusted mean [95% confidence interval]: 20.1 min [8.1, 49.8] vs. 6.2 min [3.7, 10.4], respectively, p = .04). CONCLUSION: Both adolescents with PAX6+/- and the healthy comparison group on average slept less than 8 hr/night, and overall sleep deprivation in adolescents may have masked differences between groups. This study used rare genetic disorders with biological vulnerability to sleep problems as a genotype-phenotype model. Knowledge of sleep-related phenotypes will assist in designing studies to manage sleep-related symptoms in adolescents.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[St] Status:In-Data-Review
[do] DOI:10.1177/1099800417753670

  7 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29426455
[Au] Autor:Forlini M; Date P; Gruber B; Forlini C
[Ad] Address:Institute of Ophthalmology, University of Parma, Parma, Italy.
[Ti] Title:Bilateral simultaneous artificial iris implantation for post-traumatic aniridia: a case report.
[So] Source:Can J Ophthalmol;53(1):e24-e27, 2018 Feb.
[Is] ISSN:1715-3360
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180210
[Lr] Last revision date:180210
[St] Status:In-Data-Review

  8 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29178648
[Au] Autor:Riera M; Wert A; Nieto I; Pomares E
[Ad] Address:Departament de Genètica, Institut de Microcirurgia Ocular (IMO), Barcelona, Spain.
[Ti] Title:Panel-based whole exome sequencing identifies novel mutations in microphthalmia and anophthalmia patients showing complex Mendelian inheritance patterns.
[So] Source:Mol Genet Genomic Med;5(6):709-719, 2017 11.
[Is] ISSN:2324-9269
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Microphthalmia and anophthalmia (MA) are congenital eye abnormalities that show an extremely high clinical and genetic complexity. In this study, we evaluated the implementation of whole exome sequencing (WES) for the genetic analysis of MA patients. This approach was used to investigate three unrelated families in which previous single-gene analyses failed to identify the molecular cause. METHODS: A total of 47 genes previously associated with nonsyndromic MA were included in our panel. WES was performed in one affected patient from each family using the AmpliSeq Exome technology and the Ion Proton platform. RESULTS: A novel heterozygous OTX2 missense mutation was identified in a patient showing bilateral anophthalmia who inherited the variant from a parent who was a carrier, but showed no sign of the condition. We also describe a new PAX6 missense variant in an autosomal-dominant pedigree affected by mild bilateral microphthalmia showing high intrafamiliar variability, with germline mosaicism determined to be the most plausible molecular cause of the disease. Finally, a heterozygous missense mutation in RBP4 was found to be responsible in an isolated case of bilateral complex microphthalmia. CONCLUSION: This study highlights that panel-based WES is a reliable and effective strategy for the genetic diagnosis of MA. Furthermore, using this technique, the mutational spectrum of these diseases was broadened, with novel variants identified in each of the OTX2, PAX6, and RBP4 genes. Moreover, we report new cases of reduced penetrance, mosaicism, and variable phenotypic expressivity associated with MA, further demonstrating the heterogeneity of such disorders.
[Mh] MeSH terms primary: Anophthalmos/genetics
Microphthalmos/genetics
[Mh] MeSH terms secundary: Amino Acid Sequence
Animals
Anophthalmos/diagnosis
Base Sequence
DNA Mutational Analysis
Heterozygote
Humans
Inheritance Patterns
Microphthalmos/diagnosis
Mosaicism
Mutation, Missense
Otx Transcription Factors/genetics
PAX6 Transcription Factor/genetics
Pedigree
Polymorphism, Single Nucleotide
Retinol-Binding Proteins, Plasma/genetics
Sequence Alignment
Whole Exome Sequencing
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (OTX2 protein, human); 0 (Otx Transcription Factors); 0 (PAX6 Transcription Factor); 0 (PAX6 protein, human); 0 (RBP4 protein, human); 0 (Retinol-Binding Proteins, Plasma)
[Em] Entry month:1801
[Cu] Class update date: 180207
[Lr] Last revision date:180207
[Js] Journal subset:IM
[Da] Date of entry for processing:171128
[St] Status:MEDLINE
[do] DOI:10.1002/mgg3.329

  9 / 2820 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29378178
[Au] Autor:Vazirani J; Nair D; Shanbhag S; Wurity S; Ranjan A; Sangwan V
[Ad] Address:Cornea and Anterior Segment Services, Tej Kohli Cornea Institute, L V Prasad Eye Institute, GMR Varalakshmi Campus, Visakhapatnam, India; Center for Excellence in Cornea & Ocular Surface Disorders, Excel Eye Care, Ahmedabad, India.
[Ti] Title:Limbal Stem Cell Deficiency - Demography And Underlying Causes.
[So] Source:Am J Ophthalmol;, 2018 Jan 26.
[Is] ISSN:1879-1891
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: To determine the demographic features of patients affected by limbal stem cell deficiency (LSCD), and to identify the underlying causes of LSCD DESIGN: Retrospective, multi-center case series SETTING: Two large tertiary care ophthalmology hospitals SUBJECTS: Patients with a diagnosis of LSCD presenting from January 1, 2005 to December 31, 2014 METHODS: Records of patients with a clinical diagnosis of LSCD were reviewed. Demographic details and clinical features at presentation, as well as the underlying cause of LSCD (if identified) were noted. Descriptive statistical analysis and chart preparation were done. MAIN OUTCOME MEASURES: Type of LSCD (unilateral or bilateral), age and sex of patients, extent of LSCD (clock hours of limbus involved) and underlying cause of LSCD RESULTS: We found 1331 patients with LSCD in the ten year period under study. Unilateral LSCD was more common (791 patients) than bilateral LSCD (540 patients). Out of 1331 patients, 875 (65.74%) were male. The median age of patients was 24 years. Extent of LSCD could be determined in 1849 eyes, of which 1239 eyes (67%) had total LSCD. The underlying cause of LSCD could be identified in 1512 eyes. In cases of unilateral LSCD, ocular surface burns was the commonest identifiable cause ( 83.73%). The leading identifiable causes of bilateral LSCD were ocular surface burns (29.95%), allergic conjunctivitis (29.48%), Stevens Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) (23.11%), aniridia (9.43%) and mucous membrane pemphigoid (3.54%). Lime ("chuna") injury was responsible for ocular surface burns in 352 (62.08%) out of 567 cases in which the agent was identified. CONCLUSIONS: In our study, unilateral LSCD was more common than bilateral LSCD. Young males were commonly affected, with a majority of eyes suffering from total LSCD. Overall, ocular surface burns are the leading cause of LSCD.Unilateral and bilateral LSCD had a markedly different distribution of causes, necessitating different approaches to management.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180129
[Lr] Last revision date:180129
[St] Status:Publisher

  10 / 2820 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29345189
[Au] Autor:Meng Q; Dai M; Nie X; Zhang W; Xu X; Li J; Mu H; Liu X; Qin L; Zhu X; Yan J; Zheng M
[Ad] Address:1 Orthopedics Department, Yancheng City No. 1 People's Hospital, Yancheng, P.R. China.
[Ti] Title:MicroRNA-19 contributes to the malignant phenotypes of osteosarcoma in vitro by targeting Pax6.
[So] Source:Tumour Biol;40(1):1010428317744704, 2018 Jan.
[Is] ISSN:1423-0380
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:This study was conducted to detect the expression of miR-19 and Pax6 (Paired box protein 6) in human osteosarcoma cells and the effects on biological characteristics of osteosarcoma cells. Quantitative real-time polymerase chain reaction was used to detect the expression of Pax6 and miR-19 in normal human osteoblasts (hFOB 1.19) and osteosarcoma cell lines (U2OS, Saos-2, and MG-63). Results showed that miR-19 was significantly upregulated in osteosarcoma cell lines compared with that in hFOB 1.19 cells, while the expression of Pax6 messenger RNA was significantly downregulated. Pax6 was defined as the target gene of miR-19 which was validated by luciferase reporter gene analysis. Results indicated that miR-19 had an interaction with Pax6 3'-untranslated region. At the same time, the protein expression of Pax6 was significantly decreased in the MG-63 cells transfected with miR-19 mimic and was notably enhanced in osteosarcoma MG-63 cells transfected with miR-19 inhibitor. These data suggested that Pax6 was a target of miR-19 in osteosarcoma MG-63 cells. The effects of miR-19 on the biological behavior of MG-63 cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, flow cytometry, and Transwell assay. Results showed that the downregulation of miR-19 inhibited cell viability, reduced the percentage of cells in S phase and the number of cells passing through the Transwell chamber, and increased the number of apoptotic cells. Western blot analysis showed that the inhibition of miR-19 significantly increased the expression of epithelial proteins (E-cadherin and ß-catenin) and decreased the expression of mesenchymal protein (Vimentin), extracellular signal-regulated kinase, and phosphorylated extracellular signal-regulated kinase in MG-63 cells. MiR-19 inhibitor and Pax6 small interfering RNA were simultaneously transfected into MG-63 cells. Results from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, flow cytometry, and Transwell assay demonstrated that the inhibition of Pax6 expression in MG-63 cells could reverse the cell biological effects induced by the inhibition of miR-19 expression. Based on these findings, it was suggested that miR-19, upregulated in osteosarcoma cells, negatively regulated the expression of Pax6, which can promote the malignant phenotypes of osteosarcoma cells via activation of the extracellular signal-regulated kinase signaling pathways. Therefore, miR-19/Pax6 may offer potential for use as a target for the treatment of osteosarcoma.
[Mh] MeSH terms primary: Bone Neoplasms/pathology
Gene Expression Regulation, Neoplastic/genetics
MicroRNAs/metabolism
Osteosarcoma/pathology
PAX6 Transcription Factor/metabolism
[Mh] MeSH terms secundary: Bone Neoplasms/genetics
Bone Neoplasms/metabolism
Cell Line, Tumor
Cells, Cultured
Humans
MicroRNAs/genetics
Osteosarcoma/genetics
Osteosarcoma/metabolism
Phenotype
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (MIRN19 microRNA, human); 0 (MicroRNAs); 0 (PAX6 Transcription Factor); 0 (PAX6 protein, human)
[Em] Entry month:1801
[Cu] Class update date: 180129
[Lr] Last revision date:180129
[Js] Journal subset:IM
[Da] Date of entry for processing:180119
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317744704


page 1 of 282 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information